Georgia

Global health R&D delivers for Georgia

Click here to select a new state Download PDF

Select a new state

US government investment in global health R&D has delivered

$349.1 million

to Georgia research institutions

5,800+ new jobs

for Georgia

Neglected diseases in Georgia

Chikungunya cases

Dengue cases

HIV diagnoses

24140

Malaria cases

534

Tuberculosis cases

3299

West Nile cases

190

Zika cases

110

Georgia's top USG-funded global health R&D institutions

Centers for Disease Control and Prevention (self-funding & other agency transfers)

$129.8 million

Emory University

$147.8 million

University of Georgia

$61 million

Morehouse School of Medicine

$4.7 million

Georgia State University

$4.1 million

Augusta University College of Education (formally Georgia Regents University)

$745 thousand

Mercer University

$252 thousand

Medical College of Georgia

$204 thousand

Atlanta Research and Education Foundation

$55 thousand

Georgia industry in global health R&D

Arthify

Location(s): Duluth

Geovax

Location(s): Atlanta

Novartis

Location(s): Duluth

Pathens

Location(s): Athens

Sanofi

Location(s): Forest Park

Westat

Location(s): Atlanta

Georgia's top areas of global health R&D by USG funding

29.9%

HIV/AIDS

13.9%

Malaria

25.3%

Tuberculosis

4.2%

Ebola/viral hemorrhagic fevers

3.2%

Bacterial pneumonia & meningitis

16.2%

Neglected tropical diseases

Buruli ulcer

Dengue

Helminths

Kinetoplastids

Trachoma

7.3%

Other

Diarrheal diseases

Salmonella infections

Global health R&D at work in Georgia

Emory University School of Medicine is supporting early stage clinical trials of a vaccine to prevent infection with chikungunya virus. Chikungunya is transmitted by mosquitoes and can cause persistent, debilitating joint pain. The virus, originating in Africa, arrived in the Caribbean several years ago and has since infected more than 2 million people in the Americas, including in the Florida Keys. If approved, the vaccine could be a powerful tool for protection.

Footnotes

Methodology
USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
Case study photo: Pan American Health Organization